Abstract
Neuroendocrine tumours are a heterogeneous group of neoplasms with various clinical presentations, growth rates and responses to available therapies. Studies published in 2012 have provided insights into tumour-cell signalling that will increase our knowledge of tumour biology and molecular genetics, making it possible to personalize patient care.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Clinical Trials as Topic
-
Everolimus
-
Humans
-
Neuroendocrine Tumors / drug therapy
-
Neuroendocrine Tumors / genetics
-
Neuroendocrine Tumors / metabolism*
-
Pancreatic Neoplasms / drug therapy
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / metabolism*
-
Precision Medicine
-
Receptor, Fibroblast Growth Factor, Type 4 / genetics
-
Signal Transduction*
-
Sirolimus / analogs & derivatives
-
Sirolimus / therapeutic use
Substances
-
Antineoplastic Agents
-
Everolimus
-
FGFR4 protein, human
-
Receptor, Fibroblast Growth Factor, Type 4
-
Sirolimus